Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01451619 | A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155) | PHASE1 | COMPLETED | 60 | — | — | Nov 1, 2011 | Apr 1, 2012 | Mar 25, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| Laropiprant | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Laropiprant | DRUG | One 100-mg tablet orally once daily for 4 weeks |
| Placebo for Laropiprant | DRUG | One tablet orally once daily for 4 weeks |
Inclusion Criteria: * Moderate to severe erythematotelangiectatic rosacea with moderate to severe erythema of facial lesion * Generally healthy excluding rosacea * Presence of telangiectasia * Five or less facial inflammatory lesions * Able to restrict diet in order to avoid foods/drinks (including...